{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:13:36Z","timestamp":1793643216764,"version":"4.5.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010648","name":"KU Leuven Hospital","doi-asserted-by":"publisher","award":["C14\/19\/100"],"award-info":[{"award-number":["C14\/19\/100"]}],"id":[{"id":"10.13039\/501100010648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euo.2025.12.005","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:39:13Z","timestamp":1767011953000},"page":"598-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Final Results of the Randomised Phase 2 Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer (ARNEO)"],"prefix":"10.1016","volume":"9","author":[{"given":"Alexander","family":"Giesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtan","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloefar","family":"Ahmadi Bidakhvidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annouschka","family":"Laenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Baldewijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gevaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannic","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Van Haute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Goeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"De Meerleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlien","family":"Berghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wout","family":"Devlies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Claessens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Van Poppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Everaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3195-9890","authenticated-orcid":false,"given":"Steven","family":"Joniau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.12.005_b0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.juro.2006.08.057","article-title":"Changing nature of high risk patients undergoing radical prostatectomy","volume":"177","author":"Kane","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.12.005_b0010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1464-410X.2010.09594.x","article-title":"Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy","volume":"107","author":"Walz","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.12.005_b0015","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/pros.24041","article-title":"Prostate cancer\u2010specific mortality burden by risk group among men with localized disease: implications for research and clinical trial priorities","volume":"80","author":"Dee","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2025.12.005_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.38550","article-title":"Performance of a prostate-specific membrane antigen positron emission tomography\/computed tomography-derived risk-stratification tool for high-risk and very high-risk prostate cancer","volume":"4","author":"Xiang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2025.12.005_b0025","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.12.005_b0030","series-title":"Presented at the EAU Annual Congress, Madrid","article-title":"EAU guidelines","author":"European Association of Urology","year":"2025"},{"key":"10.1016\/j.euo.2025.12.005_b0035","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer","volume":"18","author":"Devos","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2025.12.005_b0040","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/pcan.2017.29","article-title":"The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer","volume":"20","author":"Tosco","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.12.005_b0045","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13045-020-00978-z","article-title":"Novel therapies are changing treatment paradigms in metastatic prostate cancer","volume":"13","author":"Powers","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.euo.2025.12.005_b0050","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.005_b0055","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12885-018-4275-z","article-title":"Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial","volume":"18","author":"Tosco","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2025.12.005_b0060","doi-asserted-by":"crossref","first-page":"163.e7","DOI":"10.1016\/j.urolonc.2014.11.018","article-title":"Natural history of surgically treated high-risk prostate cancer","volume":"33","author":"Briganti","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.005_b0065","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2025.12.005_b0070","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.euo.2025.04.011","article-title":"Direct treatment of all visible tumour in synchronous oligometastatic prostate cancer: total eradication of tumour or the full Monty treatment","volume":"8","author":"Giesen","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.005_b0075","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/pros.24653","article-title":"Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer","volume":"84","author":"Ravi","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2025.12.005_b0080","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/JU.0000000000001632","article-title":"Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials","volume":"205","author":"McKay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.12.005_b0085","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.eururo.2025.01.015","article-title":"Long-term outcomes and prognostic impact of residual cancer burden after intensified neoadjuvant therapy in high-risk prostate cancer","volume":"87","author":"Ravi","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.005_b0090","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eururo.2025.02.025","article-title":"When less is more: the challenges of defining residual disease following neoadjuvant hormonal therapy in prostate cancer","volume":"87","author":"Devos","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.005_b0095","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/JU.0000000000003876","article-title":"A prospective randomized trial of neoadjuvant chemohormonal therapy vs hormonal therapy in locally advanced prostate cancer treated by radical prostatectomy","volume":"211","author":"Qian","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.12.005_b0100","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/jpm13040641","article-title":"Neoadjuvant androgen receptor signaling inhibitors before radical prostatectomy for non-metastatic advanced prostate cancer: a systematic review","volume":"13","author":"Yanagisawa","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.euo.2025.12.005_b0105","doi-asserted-by":"crossref","first-page":"830.e17","DOI":"10.1016\/j.urolonc.2021.04.031","article-title":"Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center","volume":"39","author":"W\u00fcrnschimmel","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.005_b0110","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2011.11.043","article-title":"Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer","volume":"61","author":"Briganti","year":"2012","journal-title":"Eur Urol"},{"issue":"15_suppl","key":"10.1016\/j.euo.2025.12.005_b0115","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1200\/JCO.2019.37.15_suppl.5079","article-title":"CALGB 90203 (Alliance): radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC)","volume":"37","author":"Eastham","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.euo.2025.12.005_b0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS285","volume":"40","author":"Kibel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.12.005_b0125","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.euo.2024.04.004","article-title":"The state of intermediate clinical endpoints as surrogates for overall survival in prostate cancer in 2024","volume":"7","author":"Miszczyk","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.005_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110256","article-title":"Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials","volume":"195","author":"Nabid","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2025.12.005_b0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2024.09.009","article-title":"Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): a pooled analysis of five randomized trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) consortium","volume":"87","author":"Ong","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.005_b0140","article-title":"Initial quality of life and toxicity analysis of a randomized phase 3 study of moderately hypofractionated radiation therapy with or without androgen suppression for intermediate-risk adenocarcinoma of the prostate: PCG GU003","volume":"8","author":"Laughlin","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.euo.2025.12.005_b0145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.euo.2024.04.018","article-title":"Functional outcomes and quality of life in high-risk prostate cancer patients treated by robot-assisted radical prostatectomy with or without adjuvant treatments","volume":"8","author":"Devlies","year":"2025","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125003311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125003311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T19:48:01Z","timestamp":1785095281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125003311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2588931125003311"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.12.005","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final Results of the Randomised Phase 2 Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer (ARNEO)","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}